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Abstract
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Measurement of the electron transfer cascade (ETC) enzyme activities and their kinetic profiles is
important in assessing mitochondrial function in the nervous system in health and disease, or
following exposure to toxic agents. The optimization of enzymatic assays for brain tissues and
neuronal cells are critical to the development of high-throughput assay formats. We describe a
step-by-step protocol for reliable and reproducible assessment of the ETC enzyme kinetics
(Complex-I through Complex-IV) for mitochondria from small quantities of tissue from different
brain regions, such as the hippocampus, cerebellum, and frontal cortex, or from neuronal cells in
culture. Methods for differential and density gradient centrifugation are detailed for cell body and
synaptic mitochondria isolation from brain, as are those for measurement of ETC activities in
micro-well plate or single-cuvette format using spectrophotometric methods. We have constructed
easy-to follow assay layouts and useful tips to perform these assays under 3 hours.

Keywords
Brain subcellular fractionation; Primary neuronal cultures; Neuroblastoma cultures; Electron
transport chain enzymes; mitochondria
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INTRODUCTION
As summarized in the historical accounting by Ernster and Schatz (Ernster & Schatz, 1981),
investigations into the role of mitochondria in cell growth, differentiation, and viability
began in 1890 with the first description of mitochondria as subcellular structures in
eukaryotic cells.
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Mitochondria in eukaryotic cells vary in number and location according to the cell type.
Human cells contain about 1,000–2,000 mitochondria per cell depending on the cellular
demands for chemical energy in the form of ATP, cellular calcium (Ca2+) buffering capacity,
cell signaling through the generation of reactive oxygen species (ROS), or import and
degradation of damaged proteins. However, some of these processes, such as oxidative
phosphorylation, if partially inhibited, would lead to an increase in ROS formation, cell
protein damage, and possible cell death (Kohen & Nyska, 2002). It is well established that
mitochondria are key to the phenomenon of programmed cell death or apoptosis occurring
under conditions of cell stress, such as tissue ischemia and reperfusion (Ravagnan, Roumier,
& Kroemer, 2002).
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From the perspective of toxicological processes that might involve altered mitochondrial
function and cell damage, especially in the nervous system, the example of Parkinson’s
disease (PD) is the most prominent one. Models of this disease have been produced by
inhibiting mitochondrial enzymes (Complex I) of oxidative phosphorylation (OXPHOS) by
pesticides or other chemical agents (Nicklas, Vyas, & Heikkila, 1985; Sherer et al., 2007).
Substantial evidence has also been accumulating pointing to the relationship between
mitochondrial stress or malfunction and the incidence of Alzheimer’s disease (Swerdlow,
2012). Loss of activity or amyloid β (Aβ)-induced inhibition of enzymes involved in
OXPHOS, in particular Complex I (NADH:ubiquinone oxidoreductase) and Complex IV
(cytochrome oxidase), are characteristic of AD or AD cell models (Bobba et al., 2013).
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Based on the observations pointing to the importance of mitochondria in brain toxicology
and human disease, especially that OXPHOS enzymes are targets of toxic agents, it is
important to describe techniques that would be useful in the study of the OXPHOS enzymes.
Also, as it has been shown that mitochondria isolated from different brain regions or
different compartments of neurons (synaptic vs. somatic mitochondria) may exhibit different
susceptibilities to damaging agents (Wang et al., 2016), it is important to use techniques that
allow for the study of both types of mitochondria.

BASIC PROTOCOL 1
Purification of somatic and synaptic mitochondria from rodent brain

Author Manuscript

There are differential characteristics in mitochondria derived from soma and the synaptic
nerve endings (e.g. axonal and dendritic). Development of subcellular fractionation
techniques with brain tissue has made it possible to obtain highly enriched preparations of
synaptic terminals (Cotman & Matthews, 1971; Cotman & Taylor, 1972; De Robertis, 1967;
Gurd, Jones, Mahler, & Moore, 1974) from which it is possible to isolate mitochondria of
the synaptic region. During homogenization of brain tissue in an iso-osmotic medium, the
axon terminals are sheared off from the axons. These nerve-ending particles (synaptosomes)
reseal into microscopic structures containing the organelles present at nerve terminals and
postsynaptic dendrites, including the mitochondria within these processes (Cotman &
Taylor, 1972).
Materials—Brain tissue homogenization Buffer (see Reagents and Solutions)
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Resuspension Buffer (see Reagents and Solutions)
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Ficoll Density Gradient Solution (see Reagents and Solutions)
Mitochondrial Storage Buffer (see Reagents and Solutions)
Synaptosome Lysis Buffer (see Reagents and Solutions)
Sucrose Density Gradient Buffer for isolation of synaptic mitochondria (see Reagents and
Solutions)
Equipment—Small animal guillotine with sharp blade
Sharp, straight edge surgical scissors

Author Manuscript

Small bone cutters
Curved forceps or tweezers with teeth
Curved forceps
Small sharp scissors
Potter-Elvehjem glass homogenizer tubes of various volumes (3 – 45 mL Thomas Scientific)
Teflon pestles (0.13 mm clearance)

Author Manuscript

Adjustable speed motor for brain homogenization—Eberbach homogenizer for Teflon-glass
Potter-Elvehjem homogenization pestle and tube (Thomas Scientific).
Polycarbonate 50 mL tubes (8 or more) with screw-caps
A rotor that can accommodate tubes that hold 20 mL or larger volumes such as a JA-20
rotor, Beckman-Coulter
A refrigerated preparative centrifuge that can create a centrifugal force of 40 – 50,000 × g’s
such as a Beckman-Coulter Avanti JXN-26 centrifuge.
Thin wall polyallomer 38.5 mL ultracentrifuge tubes (Beckman-Coulter).
An ultracentrifuge that can create 65,000 – 500,000 × g’s with a swinging bucket rotor for
the
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Ficoll density gradients such as Beckman-Coulter Optima XE ultracentrifuge with an SW28
rotor, or Thermo-Sorvall WX ultracentrifuge with the same rotor.
Isolation of somatic (free) mitochondria
1.

Fully anesthetize a lab rodent and use a small animal guillotine (decapitator,
Stoelting) to decapitate it.
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Handle the animals according to the protocol approved by your institutional
animal care and use committee (IACUC). The animals should be fully
anesthetized by CO2 inhalation prior to initiation of the procedure. Use a small
animal guillotine (decapitator, Stoelting) to decapitate it. Maintain the guillotine
free of blood or hair and, periodically, have the blade sharpened professionally as
recommended by the animal care unit of your institution.

Author Manuscript
Author Manuscript

2.

Rinse the blood from the neck region with ice-cold homogenization buffer

3.

Use straight edge scissors to cut under the scalp at the posterior end of the head
and reflect the scalp in the direction of the eyes

4.

Use the tips of the surgical bone cutters and cut the bone surrounding the point of
insertion of the spinal cord to the brainstem—cut laterally moving towards the
side of each ear lobe.

5.

Open the skull to expose the dorsal surface of the brain using a forceps or
tweezers with teeth by lifting the skull in the direction of the nose.

6.

Scoop the brain out of the skull by using a curved clamp

7.

Quickly weigh the brain and transfer it to a beaker containing homogenization
buffer kept on ice. If there is too much blood that the buffer in the beaker turns to
dark pink color, then remove the buffer and replace it with fresh buffer until the
buffer color remains either colorless or very faint pink color.

8.

Using a small sharp scissors mince each brain tissue in a small volume of the
Homogenization Buffer in a beaker on ice.

9.

Transfer the tissue to a cold glass Potter-Elvehjem homogenization tube with a
Teflon pestle.
Homogenize each minced brain tissue in the Homogenization Buffer at a ratio of
10 mL Homogenization Buffer per gram of tissue weight. Use 8–10 strokes up
and down with the pestle driven at 1,000–1,500 rpm. The sheering action leads to
complete homogenization. Intermittently put the homogenization tube into ice to
prevent heating of the vessel and denaturing proteins.
Brain tissue samples should always be kept at 0°C-to-4°C throughout the subfractionation procedure. Pre-cool the rotors, tubes, and centrifuges before use.
Keeping the tissue cold and adding protease inhibitors prevents activation of
proteases. It is advisable to include a phosphatase inhibitor cocktail in the
preparation steps as well.

Author Manuscript

10.

When homogenization is complete, measure, record the volume of the
homogenate, and remove a small aliquot for protein determination later.
It is advisable at each step in the isolation of the subfractions to keep track of the
total volume of each fraction and to remove a small aliquot of the sample for
measurement of the protein concentration (mg/mL). By multiplying protein
concentration times, the total volume of each fraction ([protein] mg/ml X Vol.
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(ml) ), you may monitor the protein recovery at each step of the purification
procedure and assess the reproducibility of the isolation method.
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11.

Transfer the homogenates to pre-cooled centrifuge tubes and centrifuge at 1,000
× g for 5 min at 4°C in a preparative centrifuge (see equipment above) to remove
cell nuclei and cell debris.

12.

Collect the supernatant from each tube and transfer to new centrifuge tubes precooled at 0°C-to-4° C.

13.

Wash the pellet with about 2 mL of Homogenization Buffer and re-suspend the
pellet with a pre-cooled pestle followed by vortexing

14.

Add to the re-suspended pellet Homogenization Buffer at the rate of 5 mL per
gram of original brain tissue

15.

Centrifuge at 1,000 × g for 5 min at 4°C and combine the supernatants from the
two centrifugations

16.

Centrifuge the supernatants at 13,000 × g for 10 min at 4oC in a preparative
centrifuge to obtain the pellet of crude mitochondrial fraction that contains free
somatic mitochondria and synaptosomes (Discard the supernatant)

17.

Add 2 mL of the Resuspension Buffer to each pellet, vortex and gently resuspend the pellet by using a Pasteur pipette to triturate the pellet

Author Manuscript

Isolation of synaptosomes and synaptic mitochondria involves several steps in
which subfractions are precipitated under high centrifugal force, and the pellets
must be resuspended in fresh medium. The re-suspended fractions must be
homogeneous, no chunks or particles. Gently dislodging the pellet from the
centrifuge tube by adding a small amount of the medium, mildly vortexing the
tube, transferring the sample to a small Teflon-glass homogenizer, and hand
homogenizing the sample gently is an effective way of preparing each
subfraction for the next step. Alternatively, you may use a Pasteur pipette and
gently triturate the sample up and down until it becomes homogeneous.

Author Manuscript

18.

Measure and record the volume and save a small aliquot for protein
determination, then transfer the resuspension to graduated cylinders and add
more Resuspension Buffer to bring the suspensions to a volume of 17.5 mL per
brain preparation

19.

Prepare the Ficoll gradients by adding 10 mL of the 14% Ficoll solution to the
bottom of a polyallomer ultracentrifuge tube (38.5 mL capacity). Layer 10 mL of
the 8% Ficoll solution on top of the 14% Ficoll. Layer 17.5 mL of the
resuspended crude mitochondrial sample on top of the 8% Ficoll (see Fig. 1)
Ficoll rather than sucrose is used for preparing the discontinuous density gradient
to isolate the synaptosomes because it preserves their structure (Cotman &
Matthews, 1971).
Ficoll has a much higher molecular mass than sucrose, therefore, a much lower
molar concentration of Ficoll is needed to achieve the same density as sucrose.
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An alternative procedure would be to use density gradients formed by Percoll
(Dunkley, Jarvie, Heath, Kidd, & Rostas, 1986).
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20.

Add Resuspension Buffer as needed to balance the weight of each tube and to
nearly fill the tubes for the centrifugation.

21.

The samples are now ready to perform discontinuous Ficoll density gradient
centrifugation in an ultracentrifuge (Thermo Sorvall WX ultracentrifuge, or
Beckman-Coulter Optima XE with a swinging bucket rotor such as SW28).

22.

Centrifuge at 63,000 × g for 50 min—the synaptosomes form a band at the
interface of 8 and 14% Ficoll whereas the somatic (free) mitochondria from
both neurons and glia are in the pellet (see Fig. 1).

23.

Use a Pasteur pipette to aspirate the upper band and the liquid above it

24.

Collect the synaptosome band by introducing the tip of a clean Pasteur pipette
near the wall of the tube at the interface of the two Ficoll layers, and transfer the
synaptosomes to a tube for a fixed angle rotor (e.g. Beckman-Coulter Type 70 Ti)

25.

After removing all Ficoll solution from each tube, re-suspend the pellet of
neuronal/glial somatic mitochondria in 0.25-to-0.5 mL of Mitochondrial Storage
Buffer

26.

Obtain a small sample (3x2013;10 μL) of the re-suspended mitochondria for
protein determination to be performed later.

27.

The mitochondrial suspension in Mitochondrial Storage Buffer may be snap
frozen for later use—Dilute the suspension to a protein concentration of 2–10
mg/mL, divide into aliquots of 100x2013;250 x00B5;L, freeze rapidly in liquid
nitrogen, and store at −80°C

Isolation of synaptic mitochondria

Author Manuscript

28.

Dilute the synaptosome fractions with 4 volumes of the Resuspension Buffer or
enough volume to fill the tube to a level recommended by the manufacturer

29.

Centrifuge at 145,000 x g for 17 min at 4°C (Beckman-Coulter Optima xE or
Thermo Sorvall Wx ultracentrifuge) to remove the Ficoll and obtain the isolated
synaptosomes as the pellet.

30.

Discard the supernatant and retain the pellet. For the isolation of synaptic
mitochondria, add approximately 0.5 mL of the Resuspension Buffer to the
synaptosome pellet

31.

Then add 5 volumes of the hypotonic Lysis Buffer to each aliquot and transfer to
a centrifuge tube. Invert the tubes several times to mix well. Allow the tubes to
sit on ice for 20 min with intermittent gentle vortexing to allow for complete
lysis of the synaptosomes and release of synaptic mitochondria

32.

Centrifuge the samples at 45,000 x g for 14 min at 4°C in a fixed angle rotor (e.g.
Type 70 Ti). The pellet represents a mixture of synaptic membranes and synaptic

Curr Protoc Toxicol. Author manuscript; available in PMC 2020 June 01.

Agbas et al.

Page 7

Author Manuscript

mitochondria and this preparation may be used for enzyme assays of partially
purified neuronal/synaptic mitochondria
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33.

To obtain more highly purified neuronal/synaptic mitochondria preparation, you
need to perform sucrose density centrifugation to separate myelin and plasma
membrane contaminants from the mitochondria— Start by discarding the
supernatant and re-suspending the pellet in 13 mL of the 34% sucrose buffer.

34.

Prepare a discontinuous sucrose density gradient by first introducing 12 mL of
the 10% sucrose solution at the bottom of each polyallomer centrifuge tube (38.5
mL capacity) for a fixed angle rotor (e.g., Beckman-Coulter Type 70 Ti)

35.

Using a long 18-gauge needle and syringe that reaches the bottom of the tube,
slowly introduce 12 mL of the 28.5% sucrose solution to the bottom of the tube
under the 10% sucrose to form a discontinuous density gradient of 10 and 28.5%
sucrose

36.

To complete formation of the sucrose density gradient, use a long needle to
introduce the suspension of synaptic membranes and synaptic mitochondria in
34% sucrose to the bottom of the centrifuge tubes

37.

Centrifuge the gradient of 10%, 28.5%, and 34% sucrose at 90,000 x g for 35
min in the Type 70 Ti rotor. In this flotation / sedimentation condition any myelin
contaminants float to the interface between 10 and 28.5% sucrose, synaptic
membranes float to the interface between 28.5 and 34% sucrose, and neuronal/
synaptic mitochondria sediment in the 34% sucrose layer as a pellet at the
bottom of the tube

38.

Using an 18-gauge needle and a syringe, remove the 10% sucrose and the myelin
band at the interface of 10 and 28.5% sucrose, then remove the band of synaptic
plasma membranes at the interface of the 28.5% and 34% sucrose, then remove
the remaining 34% sucrose solution. Add a small volume (0.25–0.50 mL) of
Resuspension Buffer, re-suspend the purified synaptic mitochondrial pellet, and
take a small aliquot (3–10 μL) for protein determination. If the synaptic
mitochondrial subfraction is to be stored for later use, the pellet may be resuspended in Mitochondrial Storage Buffer at a protein concentration of
approximately 2–10 mg/mL, then divided into aliquots of 0.10 to 0.25 mL snap
frozen in liquid nitrogen, and stored at −80°C.

BASIC PROTOCOL 2
Author Manuscript

Dissection of select brain regions
Normal aging, aging relevant neurodegenerative disease, and protein misfolding-relevant
abnormalities are linked to the decreased capacity of ATP production. Differential
mitochondrial ETC enzyme activities are expected to be different depending on the brain
region. The procedures described in this section will serve as a guide for collection of tissue
for preparation of mitochondria-enriched preparation.
Materials—Dissection pane
Curr Protoc Toxicol. Author manuscript; available in PMC 2020 June 01.
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Surgical blades with handles or single-edged razors
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A pair of large dissection scissors
A dissection microscope with a low-heat light source. Or, a large (4–5-inch diameter) 2,3 x
powered magnifier with a stand.
Two pairs of small dissection scissors
Four or more small, thin metal spatulas
Two pairs of curved fine surgical forceps
One pair of large forceps

Author Manuscript

Animal sacrifice: Follow the steps in BASIC PROTOCOL 1
Dissection Protocols for Particular Brain Regions Cerebellum
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1.

Place the brain with the ventral side facing the dissection pane surface, exposing
the cerebellum (Fig.2A)

2.

Make a transverse cut through the brain stem at the level of the colliculi [Fig.2A
(1)]

3.

Make a second transverse cut posterior to the cerebellum, through the underlying
brain stem [Fig.2A (2)]

4.

Place this block of tissue with one of the cut surfaces down, and cut the
cerebellar peduncles with a razor blade and separate the cerebellum from the
underlying brain stem [Fig.2B (1 and 2)]

Hippocampus—The following steps describe a 2–3 minutes-rapid dissection of a rodent
hippocampus.
5.

Remove the whole brain from the calvarium by opening the lateral sides of the
skull with a pair of scissors as described elsewhere (Palkovits & Brownstein,
1983)

6.

Make a lineal incision from posterotemporal pole of one hemisphere to the
anterior pole of the frontal lobe at about 30 degree angle (Fig. 3A).

Author Manuscript

Adjust the incision depth to only the cortex and subjacent corpus callosum. Practice before
harvesting the experimental tissues to get a sense of incision depth. Use either dissection
microscope or magnifying glass for better view.
1.

Make an incision in the opposite hemisphere and separate the central cortex area
(Fig. 3B)

2.

Now you can see a pair of banana like hippocampi. Remove the hippocampal
formations as indicated in Fig. 3C.
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Prefrontal Cortex
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7.

After removal of the hippocampus, use the large forceps to fold back the cortex
into the original position (Fig. 3A in hippocampus dissection).

8.

Place the brain with the ventral side facing the dissection plate

9.

Cut off the olfactory bulb with a sharp razor blade (Fig. 4A)

The anterior commissure is well visible at this point
1.

Make the section as illustrated in Fig. 4B that contains mainly motor cortex

More detailed and colored photographs for the sectioning can be viewed in the literature
(Chiu, Lau, Lau, So, & Chang, 2007; Spijker, 2011)

Author Manuscript

BASIC PROTOCOL 3
Mitochondria-enriched tissue Preparation from brain regions
Mitochondrial respiratory chain enzyme activities vary in different regions of the brain,
depending on the energy demand of the regions. The more synaptic activities requires more
energy, hence more mitochondria population (Leong, Lai, Lim, & Clark, 1984; Mukherjee et
al., 2016). Due to the size of the regional tissue in rodent brain is limited; to isolate nearpure mitochondria population may not be sufficient to analyze enzymatic studies. Therefore,
this protocol will explain how to prepare functional mitochondria-enriched preparations
from three different regions of a mouse brain (i.e. frontal cortex, hippocampus, and
cerebellum).
Materials—Glass-glass pestle Dounce homogenizer

Author Manuscript

Small table top centrifuge
Pipettes with assorted volumes
Conical bottom microfuge tubes (1mL, 0.5 mL)
Mitochondria storage buffer (MSB) (see Reagents and Solutions)
Protein assay kit (Pierce TM BCA assay kit; Thermo Scientific; Cat#23227)
UV/Vis Spectrophotometer
Cryobox

Author Manuscript

1.

Homogenize each brain tissue harvested from selected regions (i.e. hippocampus,
frontal cortex, and cerebellum) in a pre-chilled glass-glass pestle Dounce
homogenizer (Fig. 1) (2 ml volume) with MSB in an ice-bucket. Homogenize the
tissue by hand. 25–30 strokes would be sufficient. Do not allow froth during the
homogenization.
Keep tissue: MPB ratio as ~1 g wet tissue: 9 ml MSB for a thorough
homogenization.
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Mitochondria-enriched sample is prepared by differential centrifugation method
(Fig. 1). Centrifuge the homogenate in a small tabletop centrifuge for 10 min at
800 x g at 4°C. Save the supernatant.
Use a refrigerated tabletop centrifuge such as Eppendorf 54174R. Other option is
to keep one tabletop refrigerator either in a cold-box or in a cold room)

3.

Resuspend the pellet (P1) with 1–2 mL (depending on pellet size) of cold
homogenization buffer and repeat the centrifugation described in Step-2. Discard
the P1 pellet. Save the supernatant (S1).

4.

Combine the supernatants in a conical bottom centrifugation tube.

5.

Centrifuge the combined supernatants for 10 min at 11,000 x g at 4°C. Save the
mitochondria- enriched pellet (P2) and the supernatant (S2).

Author Manuscript

Save a small aliquot (~ 25 μL) of S2 to determine the presence of Cytochrome c
oxidase as a measure of the damage level of mitochondria during the
homogenization process. This test will help to assess the fragility of
mitochondria obtained from different regions of the brain.
6.

Resuspend the mitochondria-enriched pellet in a small volume of mitochondria
storage buffer (MSB) (~100–200 μL), measure the protein concentration by BCA
protein assay, and readjust the protein concentration to 20 mg/mL if necessary.
Divide the mitochondria-enriched homogenate into 20–25 μL aliquots, snap
freeze in a bucket containing liquid nitrogen, and store the aliquots at −80°C.

It is advisable to store the mitochondria-enriched preparation as aliquots of high protein
concentration in order to minimize protein degradation.

Author Manuscript

Use low retention 0.5 mL microfuge tubes that withstand cooling to −80°C for a long time.
(VWR Cat# 20170–038; 0.5 ml conical bottom micro centrifuge tube). Label the tubes
beforehand (preferably a day before) with a colored narrow-width tape. Use fine tip black
color permanent marker. Store the aliquots in 10x10 or 9x10 cryobox and label the “front”
with arrow if not already labeled by the manufacturer. Alternatively, Tubewriter™ 360 can
be used for direct writing on the tube ( www.tubewriter.com).

SUPPORT PROTOCOL 1
Mitochondrial swelling assay

Author Manuscript

An increase in mitochondrial volume due to an influx of fluid; it occurs in hypotonic
solutions due to osmotic pressure and in isotonic solutions as a result of altered permeability
of the membranes of respiring mitochondria. Dilute suspensions of mitochondria are turbid,
and absorb and scatter visible light. A direct estimation of mitochondrial size by light
scattering indicates the physical intactness of mitochondria (Navarro & Boveris, 2004). Old
or damaged mitochondria swell more than intact mitochondria; hence, less light scattering
occurs. Therefore, less light absorption should be observed. Young, healthy, and intact
mitochondria resist swelling. This is a simple and inexpensive method to get a sense of
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mitochondria quality during the isolation process. A typical mitochondrial light scattering
pattern is shown in Fig. 1).
Materials—Microfuge tube (1.5 mL)
Disposable cuvette (1 mL; BRAND disposable semi-micro plastic cuvette, VWR Cat#
759075D)
UV/Vis Spectrophotometer
Hypotonic buffer (HB) (see Reagents and Solutions)

Author Manuscript

1.

Take an aliquot of mitochondria-enriched homogenate and adjust the protein
concentration to 1 mg/mL in HB reagent.

2.

Gently mix the suspension by inverting the tube 2x2013;3 times.

3.

Place the suspension into a 1 ml disposable micro cuvette and place in the
cuvette holder of the spectrophotometer

4.

Set the wavelength of the spectrophotometer at 540 nm

5.

Place a x201C;blankx201D; cuvette containing 1 ml HB reagent and “zero” the
spectrophotometer.

6.

Place the cuvette containing the mitochondria suspension in the
spectrophotometer

7.

Monitor and record the absorbance decrease for 10 min. Absorbance change
within ΔA540nm =0.05 indicates the intactness of mitochondria for 10 min.

Author Manuscript

BASIC PROTOCOL 4
Assays of Mitochondrial Respiratory Enzyme Complexes
Complex I (NADH:ubiquinone oxidoreductase) activity measurement—
Spectrophotometric assays of complex I can utilize either the oxidation of NADH or the
reduction of ubiquinone analogs (Trounce, Kim, Jun, & Wallace, 1996). This assay utilizes
decylubiquinone as the electron acceptor and NADH as the electron donor.
Materials
Sonicator with microtip (Branson)

Author Manuscript

96-well microtiter plate
Disposable cuvette (1 ml; BRAND disposable semi-micro plastic cuvette, VWR Cat#
759075D)
UV/Vis Spectrophotometer with thermostat
Microplate reader with thermostat
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Mitochondria rupturing hypotonic solution (see Reagents and Solutions)
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0.2 M KCN
5 mM NADH
1 mM Rotenone
1.6 mM Decylubiquinone
96-well microtiter plate assay format

Author Manuscript

1.

Take out the sufficient frozen samples from −80°C and place them in an ice bath.
Allow the samples gradually thaw.

2.

Disrupt the mitochondria-enriched preparation by sonication with 6 pulses,
power level 5 and 20% duty cycle, using a Branson sonicator with microtip
(Trounce et al., 1996)

3.

Follow the assay flow chart (Table 1) step-1 through 8 the reagent additions into
each well. Discard the leftover samples.

4.

Assay parameters:

x (Volume (μL) of mitochondria suspension): Mitochondria-enriched preparation (indicated
as SAMPLE in assay layout)
Protein solution: 10 μg /well
Volume: 250 μL

Author Manuscript

Temperature: 30°C
Absorbance: 340 nm
The pathlength: 𝓁 (cm). To be determined (see SUPPORT PROTOCOL 3)
ε for Decylubiquinone: 6.2 (mM-1 cm-1)
Specific Activity(μmole/mg protein/min) = A340nm × 0 . 250 ml/6 . 2 mM−1cm−1 × 𝓁 cm × 0 . 01
mg protein

Author Manuscript

The user should adjust the buffer volume based on the protein concentration of the
mitochondria enriched preparation. It is advisable to use a concentrated mitochondriaenriched preparation that will provide 10 μg protein in 250 μL final reaction volume in a
microplate-well.
Use ΔA340 for calculating specific Complex-I activity
(i.e., ΔA340 = A340 (−) Rotenone – A340 (+) Rotenone)
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Decylubiquinone (an analog of ubiquinone) is sparingly soluble in aqueous buffers. For
maximum solubility in aqueous buffers, dilute the ethanolic solution of decylubiquinone
with the aqueous buffer of choice. Decylubiquinone has a solubility of approximately 0.3
mg/ml in a 1:3 solution of ethanol:PBS (pH 7.2) using this method. We do not recommend
storing the aqueous solution for more than one day.
Do not use refrozen sonicated samples for measuring enzyme activity.
Refrain from isolating mitochondria from frozen tissues or cell pellets as such preparations
often produce low complex-I activity (Zheng, Shoffner, Voljavec, & Wallace, 1990)

ALTERNATE PROTOCOL 1
Single Cuvette Complex I (NADH:ubiquinone oxidoreductase) activity measurement

Author Manuscript

[adapted from Spinazzi et al., (Spinazzi, Casarin, Pertegato, Salviati, & Angelini, 2012) with
minor modifications].
This single cuvette assay format provides an alternative format for those experimentalists
who either have fewer samples to analyze or do not have microplate reader in their
laboratory.
Materials—Micro centrifuge tubes (1.5 ml)
Disposable cuvette (1 ml; BRAND disposable semi-micro plastic cuvette, VWR Cat#
759075D)
UV/Vis Spectrophotometer with thermostat

Author Manuscript

Microplate reader with thermostat
Parafilm
Mitochondria rupturing hypotonic solution (see Reagents and Solutions)
Potassium phosphate buffer (0.5 M, pH 7.5)
Fatty acid-free BSA (50 mg/ml)
10 mM KCN
10 mM NADH

Author Manuscript

1 mM Rotenone
10 mM Ubiquinone
Single cuvette assay format
1.

Add 20 – 50 μg of mitochondria-enriched preparation or isolated mitochondria to
700 μL of hypotonic buffer (20 mM HEPES/KOH, pH 7.2) in a 1.5 ml micro
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centrifuge tube. Lyse mitochondria by three cycles of freeze-thawing in this
buffer. Transfer the lysed mitochondrial fraction to a 1- ml cuvette.

3.

Prepare, in parallel, a separate cuvette containing the same quantity of reagents
and mitochondrial sample. To this, add 10 μL of 1 mM rotenone solution.

4.

Cover both cuvettes with parafilm and mix by inverting. Read the baseline
absorbance in a spectrophotometer at 340 nm for 2 min.

5.

Start the reaction by adding 6 μL of ubiquinone (10 mM) and mix by inverting
the cuvette (after covering the cuvette using parafilm) and follow the decrease in
absorbance at 340 nm for 2 min.

6.

Use ΔA340 nm for calculating the rotenone sensitive specific complex-I activity.

SUPPORT PROTOCOL 2: Addressing the turbidity problem in reaction

Author Manuscript

To the lysed mitochondrial fraction in the 1-ml cuvette add 100 μL of potassium
phosphate buffer (0.5 M, pH 7.5), 60 μL of fatty acid-free BSA (50 mg/mL 30
μL of KCN (10 mM) and 10 μL of NADH (10 mM).

Author Manuscript

2.

Materials

mixture
Sometimes the poor solubility of Coenzyme-Q analogs (i.e., ubiquinone, decylubiquinol and
others) and aqueous reaction mixture give rise to a turbidity caused by relatively high
concentration of tissue extract, which interferes with the measurement of complex-I activity.
This alternative method is based on measuring 2,6-dichloroindopehenol (DCIP) reduction by
electrons accepted from decylubiquinol, following oxidation of NADH by complex-I. This
approach was developed by Janssen et al., (Janssen et al., 2007) and successfully applied to
measuring complex-I activities in mitochondrial fractions obtained from muscle and cultured
fibroblasts.

1-mL disposable cuvette (10-mm acryl-cuvettes from Sarstedt)
UV/Vis spectrophotometer with thermostat
Dimethylsulfoxide (DMSO)
10 mM NADH
1mM Rotenone

Author Manuscript

Reaction mixture for complex-I (see Reagents and Solutions)
1.

Add 2.5 – 10 μL mitochondria-enriched suspension from tissue or 20 μL
mitochondria enriched fraction from cells into the cuvette containing the reaction
mixture for complex-I

2.

Gently mix the cuvette content by manually inverting few times
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3.

Incubate the cuvette content for 3 min in a 37°C temperature-regulated
spectrophotometer

4.

Add 20 μL of 10 mM NADH (final concentration of NADH would be 0.2 mM)
into cuvette.

5.

Measure the absorbance at 30 second intervals at A600nm for 4 min at 37°C

6.

Add 1 μL rotenone from 1 mM stock solution prepared in DMSO

7.

Measure the absorbance again at 3- second intervals at A600nm for 4 min.

8.

Use the formula as in the basic protocol to calculate the amount of DCPIP. The
molar absorptivity of DCPIP at 600 nm is ε =19.1 mM-1cm-1

Author Manuscript

Decylubiquinone, antimycinA, and rotenone are not water soluble and should be prepared in
DMSO. This protocol can be performed in 96-well microtiter plate format as well.We used
Cary/Varian 100 Bio UV-Vis spectrophotometer with thermostat

BASIC PROTOCOL 5
COMPLEx I-III (NADH-induced cytochrome-c oxidoreductase) activity measurement
In case of limited tissue or cell amounts, the mitochondrial respiration studies may not be
possible. In this case, supercomplex activity measurements would be a useful approach.

Author Manuscript

Combined complex-I and -III assay can provide a useful information on altered inner
mitochondrial membrane function and/or mitochondrial fragility (Trounce, Kim, Jun, &
Wallace, 1996). This assay measures the absorbance increase at 550 nm caused by reduced
cytochrome c (see Figure 1). Oxidized form of cytochrome c (Cyt c) functions as the
electron acceptor and NADH as donor.
Materials—Sonicator with microtip (Branson)
96-well micro titer plate (clear bottom)
1-mL disposable cuvette (10-mm acryl-cuvettes from Sarstedt)
UV/Vis spectrophotometer with thermostat
Microplate reader with thermostat
50 mM Potassium phosphate buffer (KP) (see Reagents and Solutions)

Author Manuscript

0.2 mM KCN
4 mM Cyt c (oxidized)
5 mM NADH
1mM Rotenone
Reaction mixture for complex-I (see Reagents and Solutions)
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96-well microtiter plate assay format:
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1.

Follow the BASIC PROTOCOL 4 step 1 through 2

2.

Follow the assay flow chart (Table 2) step-1 through 7 for the reagent additions
into each well. Discard the leftover samples.

3.

Assay parameters:
x (Volume (μL) of mitochondria suspension): Mitochondria-enriched preparation
(indicated as SAMPLE in assay layout)
Volume: 250 μL
Protein solution: 10 g/well Temperature: 30°C
Pathlength: 𝓁 (cm) To be determined (See SUPPORT PROTOCOL- 4 / Step 7)

Author Manuscript

ε for Cyt-c (oxidized): 8.4 mM-1 cm-1
Specific Activity(μmole/mg protein/min) = A550nm × 0 . 250 ml/8 . 4 mM−1cm−1 × 𝓁 cm

× 0 . 01 mg protein

Manufacturer provided data sheet should have the “ε” value. If not, contact their
technical support. We used oxidized Cytochrome c from equine heart (SigmaAldrich; Cat# C2506)

Author Manuscript
Author Manuscript

4.

First, add 235 μL KP Buffer in all wells labeled as “BLANK and SAMPLES (−)
rotenone “and 232.5 μL in wells labeled as “SAMPLES (+) rotenone “. Remove
the volume (μL) that will be replaced with protein samples. Small protein sample
volumes will adhere to the base of the well. This way, the minute amount of
protein solution will be mixed well in the larger volume of KP buffer.

5.

Design the 96-well microtiter plate layout in a fashion that both (+) Rotenone
and (−) Rotenone reaction mixtures can be assayed in parallel.

6.

The rotenone sensitive activity due to complex-I generally varies between 30 and
80% of the total NADH-cytochrome-c reductase activity in mitochondria
enriched preparations from different tissues or cell lines (Trounce et al., 1996)

7.

12-channel multi pipette is recommended for simultaneously adding NADH to
start the reaction

8.

Always run the assay in triplicates

9.

Crosscheck your micro plate light path value from the specification sheet or call
the technical service department of the vendor.

10.

The BioTek Synergy-HT plate reader has an auto sampler unit for addition of the
reaction starter simultaneously; however, the reservoir of the auto sampler
requires a large volume and it is not cost-effective if a few daily kinetic studies
are performed. Instead, spot 5 μL of 1 mM NADH on the side wall of a well (see
critical parameters in COMMENTARY section). Make sure that the program
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used for the plate reader includes “plate shaking before measurement”. Plate
shaking allows the spotted NADH to mix rapidly with the reagents in the wells
thus allowing for near “zero” time measurement to be obtained.
11.

For the preparation of the NADH solution, weigh the required amount of βNADH. First, add 100 μL 0.01 N NaOH to dissolve completely the β-NADH.
Finally, adjust the final volume with distilled water. Prepare this solution fresh
daily and discard any remaining solution upon completion of the assay.

ALTERNATIVE PROTOCOL 2
Single Cuvette COMPLEx I-III (NADH-induced cytochrome-c oxidoreductase) activity
measurement

Author Manuscript

This single cuvette assay format provides an alternative format for those experimentalists
who either have fewer samples to analyze or do not have microplate reader in their
laboratory.
Materials—1-mL disposable cuvette (10-mm acryl-cuvettes from Sarstedt)
UV/Vis spectrophotometer with thermostat
Hypotonic buffer (see Reagents and Solutions)
KP Buffer (see Reagents and Solutions)
Fatty acid-free BSA

Author Manuscript

10 mM KCN
10 mM NADH
1mM Rotenone
1 mM Cyto c (oxidized)
Single cuvette assay format (adapted from Spinazzi et al., (Spinazzi et al., 2012) with
minor modifications)

Author Manuscript

1.

Incubate the mitochondria-enriched preparation ([protein] = 1–6 μg) for 2 min in
in 700 μL of hypotonic buffer (20 mM HEPES/KOH, pH 7.2) in a 1-ml cuvette
to induce an osmotic shock

2.

Add 100 μL of potassium phosphate buffer (0.5 M, pH 7.5), 20 μL of fatty acidfree BSA (50 mg/ml), 30 μL of 10 mM KCN and 50 μL of 1.0 mM oxidized
cytochrome c. Adjust the volume to 980 μL with distilled water.

3.

Prepare, in parallel, a separate cuvette containing the same quantity of reagents
and sample plus 10 μL of 1 mM rotenone solution.

4.

Mix by inverting the cuvette and monitor the baseline absorbance at A550 nm for
2 min.
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5.

Start the reaction by adding 20 μL of 10 mM NADH, mix by inversion using
parafilm, and then follow the increase of absorbance at A550 nm for 2 min.

6.

Specific Complex I+III activity can be determined by ΔA550nm, which reflects
the rotenone-sensitive activity.

BASIC PROTOCOL 6
COMPLEx-II (Succinate Dehydrogenase; Succinate-Ubiquinone oxidoreductase) activity
measurement

Author Manuscript

Complex II consist of only four peptides and it is the simplest of all the complexes of the
electron transfer chain. The nature of the association of complex II with the mitochondrial
matrix membrane makes complex-II a useful mitochondrial marker enzyme (Scheffler,
2008a). The citrate synthase partially leaks out during the isolation of mitochondria from the
frozen tissues (Janssen et al., 2007); therefore, citrate synthase may not be a useful
mitochondrial marker enzyme. The following assay measures the reduction of DCPIP when
coupled to complex-II catalyzed reduction of decylubiquinone (DBH2).
Materials—Sonicator with microtip (Branson)
Microplate reader with thermostat
96-well micro titer plate (clear bottom)
Reagent mixture-I and -II (see Reagents and Solutions)
1M Malonate

Author Manuscript

2.5 mM DBH2
96-well microtiter plate assay format
1.

Follow the BASIC PROTOCOL 4 step 1 through 2

2.

Follow the assay flow chart (Table 3) step 1 through 8 for the reagent additions
into each well. Discard the leftover samples.

3.

Assay parameters:

x (Volume (μL) of mitochondria suspension): Mitochondria-enriched preparation (indicated
as SAMPLE in assay layout)

Author Manuscript

Assay volume: 250 μL / well
Protein solution: 10 μg /well
Temperature: 30°C
Light path length: 𝓁, (cm) To be determined (See SUPPORT PROTOCOL-3 )
ε for DCPIP: 19.1 mM-1 cm-1
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Specific Activity(μmole/mg protein/min) = A600nm × 0 . 250 ml/19 . 1 mM−1cm−1 × 𝓁 cm × 0 . 01
mg protein

Use 12-channel multichannel pipette to minimize the pipetting intervals between rows.
DCPIP color should be blue and scanning graph should show maximal peak at 600 nm (Fig.
1). If the color changes to purple, properly discard DCPIP and prepare a fresh solution.

ALTERNATIVE PROTOCOL 3
Single Cuvette COMPLEx-II (Succinate Dehydrogenase; Succinate-Ubiquinone
oxidoreductase) activity measurement

Author Manuscript

This single cuvette assay format provides an alternative format for those experimentalists
who either have fewer samples to analyze or do not have microplate reader in their
laboratory.
Materials—1-mL disposable cuvette (10-mm acryl-cuvettes from Sarstedt)
UV/Vis spectrophotometer with thermostat
Parafilm
Hypotonic buffer (se Reagents and Solutions)
KP Buffer (seeReagents and Solutions)

Author Manuscript

Fatty acid-free BSA
400 mM succinate
12.5 mM Decylubiquinone (DBH2)
50 mM 2-thenoyltrifluoroacetone (TTFA)
Single cuvette assay format (adapted from Spinazzi et al. (Spinazzi et al., 2012) with minor
modifications)

Author Manuscript

1.

Add 20 – 50 μg of mitochondria enriched protein sample to 700 μL of hypotonic
buffer (20 mM HEPES/KOH, pH 7.2) in a 1.5 ml micro centrifuge tube. Lyse
mitochondria by three cycles of freeze-thawing in this buffer. Transfer the lysed
mitochondrial fraction to a 1-ml cuvette.

2.

To the lysed mitochondria in the 1-ml cuvette, add 50 μL of potassium phosphate
buffer (0.5 M, pH 7.5), 20 μL of fatty acid-free BSA (50 mg /ml), 30 μL of 10
mM KCN, 50 μL of 400 mM succinate and 145 μL of 0.015 % DCPIP (wt/vol).
Adjust the volume to 996 μL with distilled water.
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3.

Cover the cuvette with parafilm and mix by inverting the cuvette and incubate
inside the spectrophotometer at 37°C for 10 min.

4.

Read the baseline activity at 600 nm for the last 2 min.

5.

Start the reaction by adding 4 μL of 12.5 mM DBH2, mix by inversion and
follow the decrease in absorbance at 600 nm for 3 min.

6.

Check the specificity of complex II activity by running the assay after the
addition of 10 μL of either 1 M malonate or 50 mM TTFA before starting the
reaction. The degree of inhibition usually exceeds 85% with TTFA and 95% with
malonate, indicating a high specificity of the reaction.

BASIC PROTOCOL 7
Author Manuscript

COMPLEx II-III (Succinate-Cytochrome-c Oxidoreductase) activity measurement
The succinate-induced cytochrome- c reduction by complex-III is the basis of this reaction.
The assay involves oxidized cytochrome-c as the electron acceptor and succinate as donor.
In this reaction setting, the fully activated complex-II is critical; therefore, the user must preincubate the mitochondria-enriched preparation with the succinate (Barrientos, Fontanesi, &
Diaz, 2009; Spinazzi, Casarin, Pertegato, Salviati, & Angelini, 2012) as indicated below in
the experimental layout.
96-well microtiter plate assay format
Materials: Sonicator with microtip (Branson)
Microplate reader with thermostat

Author Manuscript

96-well micro titer plate (clear bottom)
50 μM KCN
0.5 M Succinate
1 M Malonate
mM Cytochrome c (oxidized)

Author Manuscript

1.

Follow the BASIC PROTOCOL 4 step-1 through 2

2.

Follow the assay flow chart (Table 4) step 1 through 8 for the reagent additions
into each well. Discard the leftover samples.

3.

Assay parameters

x (Volume (μL) of mitochondria suspension): Mitochondria-enriched preparation (indicated
as SAMPLE in assay layout)
Volume: 250 μL
Protein solution: 10 μg/well
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Temperature: 30°C

Author Manuscript

Light pathlength: 𝓁, (cm) To be determined (see SUPPORT PROTOCOL 3)
ε for Cyt c (oxidase): 8.4 mM-1 cm-1
Specific Activity(μmole/mg protein/min) = A500nm × 0 . 250 ml/18 . 5 mM−1cm−1 × 𝓁 cm × 0 . 01
mg protein

It is a necessary step to preincubate the micro well content with succinate for 20 min at 37°C
is to fully activate the Succinate –Cyt c oxidoreductase enzyme.
The volume of the protein solution range would be 1–3 μL that gives 10 μg protein/well.

Author Manuscript

It is difficult to subtract 1–3 μL volume from buffer solution to meet the final volume of 250
μL. The best way is to place the same volume of buffer in all wells; then remove the volume,
which will replace with protein solution. (Let’s say you need to add 1.3 μL protein solution.
Remove 1.3-μL buffer from the well, add 1.3 μL of protein solution, and wash your pipet tip
2–3 times with the buffer.)
User may also use 1 mg/mL AntimycinA instead of 1M Malonate

ALTERNATIVE PROTOCOL 4
Single cuvette assay format COMPLEx II-III (Succinate-Cytochrome-c Oxidoreductase)
activity measurement

Author Manuscript

(adapted from Spinazzi et al. (Spinazzi et al., 2012) with minor modifications)
This single cuvette assay format provides an alternative format for those experimentalists
who either have fewer samples to analyze or do not have microplate reader in their
laboratory.
Materials—1-mL disposable cuvette (10-mm acryl-cuvettes from Sarstedt)
UV/Vis spectrophotometer with thermostat
Parafilm
Hypotonic buffer (see Reagents and Solutions)

Author Manuscript

10 mM KCN
400 mM succinate
KP Buffer (see Reagents and Solutions)
1 mM Cyto c (oxidized)
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mg/ml AntimycinA

Author Manuscript

1.

To a 1-ml cuvette, add 800 μL of distilled water, 40 μL of potassium phosphate
buffer (0.5 M, pH 7.5), 30 μL of KCN (10mM), 25 μL of succinate (400 mM)
and 1–2 μg of mitochondria-enriched suspension. Adjust the volume to 950 μL
with distilled water

2.

Mix by inverting the cuvette and incubate for 10 min inside the
spectrophotometer at 37⁰C.

3.

Start the reaction by adding 50 μL of oxidized cytochrome c (1 mM), mix by
inverting the cuvette, and then follow the increase of absorbance at A550 nm for 3
min.

4.

Check the specificity of this assay by adding 10 μL of 1 M malonate or 1 mg /ml
AntimycinA in a separate cuvette prepared as described in steps above.

BASIC PROTOCOL 8
COMPLEx-III (Ubiquinol: Ferricytochrome-c Oxidoreductase) activity measurement
This assay measures the reduction of cytochrome-c (oxidized) catalyzed by complex-III.
Complex-III is ubiquinone-cytochrome-c oxidoreductase and is often named the bc1
complex after the two cytochromes found within it; one also finds the simpler name
cytochrome c reductase in the literature (Scheffler, 2008b). The assay involves oxidized
cytochrome-c as the electron acceptor and decylubiquinone (DBH2) as donor.

Author Manuscript

96-well microtiter plate assay format
Materials: Sonicator with microtip (Branson)
96-well micro titer plate (clear bottom)
Microplate reader with thermostat
50 mM KCN
1.25 mM Cytochrome c (oxidized)
1 mM AntimycinA

Author Manuscript

5mM DBH2
Reaction Buffer for Complex-III (see Reagents and Solutions)
1.

Follow the BASIC PROTOCOL 4 step 1 through 2

2.

Follow the assay flow chart (Table 5) step 1 through 8 for the reagent additions
into each well. Discard the leftover samples.

3.

Assay Parameters
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x (Volume (μL) of mitochondria suspension): Mitochondria-enriched preparation (indicated
as SAMPLE in assay layout)
Volume: 250 μL
Protein solution: 10 μg/well
Temperature: 30°C
Light pathlength: 𝓁,(cm) To be determined (See SUPPORT PROTOCOL-4 / Step 7)
ε for Cyt c (reduced): 29.5 mM-1 cm-1
Specific Activity( μ mole/mg protein/min) = A550nmx 0 . 250 ml/29 . 5 mM−1cm−1 × 𝓁 cm × 0 . 01

Author Manuscript

mg protein

BASIC PROTOCOL 9
COMPLEx-IV (Cytochrome-c oxidase) activity measurement
Complex IV or cytochrome-c oxidase activity is a simple assay and can be easily measured
by following the oxidation of reduced cytochrome c at A500 nm. The specificity of complex
IV activity is measured by the percent inhibition following addition of potassium cyanide
(Spinazzi et al., 2011)
96-well micro titrate plate assay format

Author Manuscript

Materials: Sonicator with microtip (Branson)
96-well micro titer plate (clear bottom)
KP Buffer (see Reagents and Solutions)
50 mM KCN
mM Cyt c (reduced) (see Reagents and Solutions)

Author Manuscript

1.

Follow the BASIC PROTOCOL 4 step-1 through 2

2.

Follow the assay flow chart (Table 6) step 1 through 4 for the reagent additions
into each well. Discard the leftover samples.

3.

Assay Parameters:

x (Volume (μL) of mitochondria suspension): Mitochondria-enriched preparation (indicated
as SAMPLE in assay layout)
Volume: 250 μL / well
Protein solution: 10 μg/ well
Temperature: 30°C
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Light pathlength: 𝓁,(cm) To be determined (See SUPPORT PROTOCOLE-4 / Step 7)
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ε for Cyt-c (reduced) : 29.5 mM-1 cm-1
SpecificActivity( μ mole/mg protein/min) = A550nmx 0 . 250ml/29.5 (mM‐1cm‐1) xl cm x 0 . 01mg protein

Author Manuscript

[Cyt c (reduced)] = 20 μM /well. The dispensing volumes are small and pipetting fractional
volumes are not practical; therefore, it is a better practice to adjust the concentration rather
than pipet volume to provide desired concentration per reaction well. In case of observing
low enzyme activity, include 0.025% laurylmaltoside in reaction media. This detergent
approximately doubles the specific activity of cytochrome-c oxidase (Birch-Machin &
Turnbull, 2001). An excessive mechanical disruption during the sample preparation may
inactivate the complex IV enzyme (Zheng, Shoffner, Voljavec, & Wallace, 1990).

ALTERNATIVE PROTOCOL 5
Single Cuvette COMPLEx-IV (Cytochrome-c oxidase) activity measurement
(adapted from Spinazzi et al., (Spinazzi et al., 2012) with minor modifications)
Materials—1-mL disposable cuvette (10-mm acryl-cuvettes from Sarstedt)
UV/Vis spectrophotometer with thermostat
Parafilm
10 mM KCN

Author Manuscript

KP Buffer (see Reagents and Solutions)
1 mM Cytochrome c (reduced) (see Reagents and Solutions)

Author Manuscript

1.

To a 1-ml cuvette, add 400 μL of distilled water, 50 μL of potassium phosphate
buffer (100 mM, pH 7), reduced Cytochrome c (1 mM) and read the baseline
activity at 550 nm for the last 2 min. (see REAGENTS section how to prepare
reduced Cytochrome c solution)

2.

Adjust the volume to 995 μL with distilled water.

3.

Start the reaction by adding 1–2 μg of mitochondria-enriched preparation (in a
final volume of 5 μL) mix by inverting and monitor the decrease in absorbance at
550 nm. This takes approximately 3 min.

4.

To check the specific activity of complex IV, add 30 μL of 10 mM of KCN in a
separate reaction prepared as described above.
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SUPPORT PROTOCOL 3
CITRATE SYNTHASE ACTIVITY MEASUREMENT AND PATHLENGTH DETERMINATION
Citrate synthase (CS), a Kreb’s cycle enzyme, is commonly used mitochondrial matrix
marker enzyme (Barrientos et al., 2009; Trounce et al., 1996). CS activity is interpreted as a
reference mitochondrial enzyme with relation to the total sample protein and to the activity
of mitochondrial ETC enzymes.

Author Manuscript

The purpose of including CS activity measurement is to normalize other ETC enzyme
activities. The CS activity measurement will also determine whether the sample aliquot may
have deteriorated, resulting in nonspecific lowering of the activities of ETC enzymes (Kerr,
Grahame, & Nakouzi, 2012). Normalization of ETC enzymes based on citrate synthase
activity is best when fresh mitochondria preparation is used. The detection of citrate
synthase activity in frozen tissue or cell pack preparation may not be useful due to leakage
of citrate synthase through compromised mitochondria membrane.
Materials—Sonicator with microtip (Branson)
96-well micro titer plate (clear bottom)
Microplate reader with thermostat
10 mM oxaloacetic acid
Reaction mixture for CS (see Reagents and Solutions)
96-well micro titrate plate assay format

Author Manuscript

1.

Follow the BASIC PROTOCOL 4 step 1 through 2

2.

Follow the assay flow chart (Table 7) step 1 through 5 for the reagent additions
into each well. Discard the leftover samples.

3.

Assay Parameters:

x (Volume (μL) of mitochondria suspension): Mitochondria-enriched preparation (indicated
as SAMPLE in assay layout)
Volume: 250 μL
Protein solution: 10μg/well

Author Manuscript

Temperature: 30°C
Light pathlength: 𝓁,(cm) To be determined (See SUPPORT PROTOCOLE-4 / Step 7)
ε for DTNB: 13.6 mM-1cm-1
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Specific activity = Units μmole . ml − 1min − 1 = Slope ΔA412nm /min × 250 μl/13 . 6 mM−1cm−1 × 𝓁
cm × 0 . 01 mg

Freshly prepare this reaction mixture for each assay (1200 μL; good for 30 wells)
Normalize ETC enzyme activities by ETC enzyme activity rate / citrate synthase activity
rate.
The ratios may be used to compare enzymatic activities in different samples that will offset
the variation born from sample preparation and pipetting.
How to measure the Pathlength [l ,cm] of your sample in a 96-well microtiter plate?

Author Manuscript

When you use a 1 cm cuvette, the Pathlength is not affected by the volume of your sample as
the measurement is from the side. In the case of a 96-well microtiter plate, the measurement
is from the top and the pathlength changes with changes in the volume. The following
protocol describes two ways to calculate the pathlength (Shah, 2014):
•

Mathematical way:

Pathlength = 4 * volume / 3.14 * d2 , where “d” is diameter of a single well
•

Experimental way:

Author Manuscript

i.

Pathlength = (A977nm for water) – (A900nm for water) /0.18

ii.

Add 250 μL of water to five wells

iii.

Wait for 20 minutes at ambient temperature or gently shake for 2–3
minutes

iv.

Read the absorbance at 977nm and 900 nm

v.

Average the readings and place them in the above formula

vi.

Divide the result by 0.18

vii.

The final number is the light path length (𝓁) in centimeter

The value 0.18 corresponds to (A977nm –A900nm) of water in a 1-cm cuvette and is accepted
as default value. If you use a BIO TEK microplate reader, BIO TEK/Synergy

Author Manuscript

HT/Gen5 2.0 software has pre-loaded information about micro-well plates from different
brand names based on the buffer and kind of 96-well microtiter plate used in the assay.

ALTERNATIVE PROTOCOL 6
Single cuvette citrate synthase activity measurement
(adapted from Spinazzi et al., (Spinazzi et al., 2012) with minor modifications)
Materials—1-mL disposable cuvette (10-mm acryl-cuvettes from Sarstedt)
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UV/Vis spectrophotometer with thermostat
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Parafilm
200 mM Tris Buffer (see Reagents and Solutions)
Triton x-100
0.1 mM DTNB
10 mM Acetyl coenzyme A (acetyl-CoA)
M Oxaloacetic acid

Author Manuscript

1.

To a 1-ml cuvette, add 300 μL of distilled water, 500 μL of Tris (200 mM, pH
8.0) with triton x-100 (0.2%[vol/vol]), 100 μL of 5,5’-dithiobis (2-nitrobenzoic
acid) [DTNB], 30 μL of acetyl-CoA (10 mM) and the sample (1–2 μg of
mitochondria); Adjust the volume to 950 μL with distilled water

2.

Mix by inverting the cuvette and read the baseline activity at 412 nm for 2 min.

3.

Start the reaction by adding 50 μL of 10 mM oxaloacetic acid, mix by inverting,
and then monitor the increase in absorbance at 412 nm for 3 min.

Reagents and Solutions
Use 18 mohm (mΩ) megapure water for the reagents and solution preparation

Author Manuscript

1.

4-(2-Aminoethyl)benzenesulfonyl fluoride hydrochloride (AEBSF) (0.1 M):
Dissolve 1.18 g 4-(2-Aminoethyl)benzenesulfonyl fluoride hydrochloride in 35
ml water and adjust the volume to 50 ml with water. Aliquot into small volumes
and store at −20°C for 1–2 years.

2.

AntimycinA (10 mg/ml): Dissolve the entire vial content (25.0 mg) in 2.5 ml of
95% ethanol, ether, DMSO, and chloroform. Store 4 months at 4°C, 6 months at
−20°C, and longer (up to a year) at 80°C. Dilute the stock solution to 1 mg/ml by
adding 10 μL of stock to 90 μL of ethanol on the day of assay.

3.

Acetyl-CoA (50 mg/ml): Dissolve the entire vial content (5.0 mg) in 200 μL of
water, (It is more practical to dissolve the bottle content). Aliquot in 10–20 μL
and store at −80°C for several months.

Author Manuscript

Solubility: 100 mg/ml water. Add an additional DMSO in case of complete
dissolving is not achieved
4.

Benzamide (0.2M): Dissolve 0.24 g benzamide in 5 ml of 100% ethanol and
adjust the volume to 10 ml with ethanol. Store at −20°C for several years.

5.

Benzamidine.HCL (0.2 M): Dissolve 0.31 g benzamidine.HCl in 5 ml of 100%
ethanol and adjust the final volume to 10 ml with ethanol. Store at −20°C for
several years.
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6.

Brain Tissue Homogenization Buffer: 0.32 M sucrose, 0.5 mM MgSO4, 0.1
mM EGTA, 10 mM HEPES. Adjust pH to 7.4. Just before use, add benzamide,
benzamidine hydrochloride (HCl), and 4-(2- aminoethyl)benzenesulfonyl
fluoride-HCl (AEBSF) to the buffer to reach a final concentration of 1.1mM for
each. Also, add a commercial protease inhibitor cocktail that contains pepstatin,
bestatin, leupeptin, and aprotinin, as per the manufacturer’s instructions. Prepare
fresh solution, keep at 4°C and discard the leftover.

7.

BSA (fat-free) (50 mg/ml). Dissolve 0.25 g of defatted BSA in 5 ml of distilled
water and store it in 1-ml aliquots at 4⁰C for up to 1 month or until signs of
microbial contamination are seen.

8.

Cytochrome-c (oxidized) (2 mM): Dissolve the entire vial (50mg) in 2.0 ml of
water. Prepare 25–50 μL aliquots and store at −20oC for 6months-1 year

Author Manuscript

Cytochrome-c is sold in “oxidized” form and soluble in water (pH 7±1)
The reagent is light sensitive; therefore, use dark-color vial/tube [Argos/ Cat#
T7100BK (1.5 ml); Cat# T7456–001(0.5 ml)].
9.

DCPIP [2,6-Dichlorophenol indophenol-sodium salt hydrate] (10 mM):
Dissolve 3.0 mg DCPIP.H2O in 1 ml of water. The color of this reagent must be
blue. Store at 4oC for several weeks.
Solubility: 30 mg/ml water
If the color turns from blue to purple and aggregate forms due to storage,
prepare a fresh solution.
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10.

DTNB [5,5’-Dithiobis(2-nitrobenzoic acid)](50 mM):Dissolve 4.0 mg DTNB
in 1.0 ml of ethanol. Store at 4oC for 2 months
Solubility: 8 mg/ml ethanol
Alternatively, 5 mM DTNB can be made in about a 100 mM sodium or
potassium phosphate buffer solution, pH 7.2 containing 0.10 mM EDTA. This
solution is stable for more than two months if stored in the dark at 4°C up to 6
month.
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11.

Decylubiquinone (DBH2) stock solution (10mM). Add a few grains of
potassium borohydride to 250 μL of 10 mM DBH2 in 100% ethanol. Add 5-μL
aliquots of 0.1 M HCl until the solution becomes colorless. Briefly spin the
solution at 10,000 x g for 1 min and transfer the solution into a new 500-μL tube,
avoiding any potassium borohydride crystals. Adjust the pH of the solution
between 2 and 3 with 5-μL aliquots of 1 M HCl and keep the solution on ice
protected from light. Store at −20°C for 3 months

12.

EDTA (0.5 M): Dissolve 18.6 g EDTA disodium salt dehydrate in about 75 ml of
water. Adjust the pH to 7.5 with sodium hydroxide and adjust the final volume to
100 ml with water. Store at 4°C for at least 1 year.

Curr Protoc Toxicol. Author manuscript; available in PMC 2020 June 01.

Agbas et al.

Page 29

Author Manuscript
Author Manuscript
Author Manuscript

13.

EGTA (0.1 M): Dissolve 0.47 g EGTA in 10 ml of water. Aliquot into small
volumes and store at −20°C for 1–2 years.

14.

Ficoll Density Gradient Solution: Dissolve 14.0 g Ficoll in 100 mL of
Resuspension Buffer overnight at room temperature. Then, add all protease
inhibitors. Prepare sufficient volumes of an 8% w/v and a 14% w/v Ficoll
solution to have 10 mL of each solution for each gradient centrifuge tube. Store
at −20°C for several years.

15.

Glutamate stock solution (0.2 M): Weigh 59 mg L-Glutamic acid. Add three
drops of 5 N NaOH. Mix well. Adjust the volume to 2ml with 50 mM potassium
phosphate buffer (pH 7.4). Aliquot to 25–50 μL and store at −20oC for 1 year.

16.

HEPES (0.1 M): Dissolve 2.38 g HEPES in about 75 ml of water. Adjust pH 7.2
with 1M KOH. Adjust the final volume to 100 ml with water. Store at 4oC for 1
year.

17.

17.Hypotonic Buffer (HB): 90 mM KCL + 20 mM MOPS-KOH, pH 7.2.
Store at 4°C for 1–2 years.

18.

KCl (1 M): Dissolve 7.46 g KCl in 100 ml water. Store at room temperature for
indefinitely.

19.

KCN stock solution (10 mM). Dissolve 6.50 mg of KCN in 10 ml of distilled
water under a fume hood. Store at 4°C for 1–2 years.

20.

Malate [DL-maleic acid di-sodium salt](0.2 M): Dissolve 0.36 g malate in 10
ml of nanopure water. Aliquot in small volumes and store at 4°C for 1 year.

21.

Malonate (malonic acid) stock solution (1M): Dissolve 10.4 g malonic acid in
1N NaOH and adjust the final volume to 100 mL with distilled water. If a cloudy
appearance observed during the volume adjustment, add little more 1N NaOH.
The final reagent should look clear to slightly hazy. Store at −20°C for 1 year.

22.

Mannitol (1 M): Dissolve 19.2 g Mannitol in 100 ml of water. Store at −20oC
for 1–2 years
Solubility of Mannitol: 182 g/liter at room temperature.

Author Manuscript

23.

MOPS/KOH Buffer (pH 7.2)(0.4 M) : Dissolve 4.19 g MOPS in approximately
40 ml of nanopure water. Adjust pH to 7.2 with 1 M potassium hydroxide.
Adjust the final volume to 50 ml with water. Store at 4°C for 1 year. Check pH
before use.

24.

Mitochondria rupturing hypotonic solution: 25mM K2PO4, pH 7.2; 5 mM
MgCl2 . Store at 4°C for 1 year. Visually check before use. If a turbidity
observed, discard it and prepare fresh batch.

25.

Mitochondrial Storage Buffer (MSB): Prepare a solution containing 230 mM
Mannitol, 70 mM sucrose, 1 mM EGTA, 10 mM HEPES; pH 7.2, and add
freshly, before use, a protease inhibitor cocktail following the instructions of the
manufacturer of the cocktail. Store at 4°C for 6 months.
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26.

NADH stock solution (10mg/ml): Dissolve 10.0 mg NADH (anhydrous) in 1 ml
of Na-bicarbonate buffer, pH 9.0. The molar based concentration is 14.0 mM
Store at 2–8°C for 1 month.

27.

NaOH (5 N): Dissolve 20.0 g sodium hydroxide in a 60–70 ml of nanopure
water. Completely dissolve the pellets. Apply heat if necessary. Adjust the
volume to 100 ml with water. Store at 4°C indefinitely.
Sodium hydroxide is a corrosive chemical. Wear your personal protective
equipment (i.e., lab coat, gloves, and goggle).

28.

Oligomycin (10mg/ml): Dissolve the entire vial (50 mg) in 0.5 ml of ethanol.
Aliquot in 20 μL and store at −70oC.
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Stability of oligomycin in different temperature settings: 2–3 weeks at 4oC.
Several months at −20oC. Longer storage period at −70oC
Oligomycin can be dissolved in ethanol, ether, DMSO, or acetone. The solubility
is 250 mg/mL
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29.

OAA (Oxaloacetic acid) stock solution (100mM): Weigh 6.60 mg OAA and
dissolve in 500 μL of water. Keep on ice and prepare daily since oxaloacetic acid
undergoes decarboxcylation in solution to form pyruvate and is therefore
unstable.

30.

Phenazine metasulfate [N-methylphenazonium methyl sulfate] (0.1 M):
Dissolve 31 mg phenazine metasulfate in 1 ml of nanopure water at room
temperature. Store at −20°C for 3–4 months protected from light.

31.

Protease inhibitor cocktails : Protease Inhibitor Cocktail Set III;
Calbiochem( Cat# 539134). Following initial thaw, aliquot and store at-20°C for
2–3 years.

32.

Potassium phosphate Buffer (KP) (0.5 M, pH 7.5): Follow the preparation
protocol in “Short Protocols in Molecular Biology”, Fourth Ed. Page A1–30.
Store at 4°C for 1 year.

33.

Reaction Buffer for complex-III: 0.25 M sucrose; 1 mM EDTA; 50 mM TrisHCl, pH 7.4 in 10 ml. Store on ice until use. Prepare daily.

34.

Reaction mixture for citrate synthase (CS) reaction: 1M Tris-HCl, pH 7.8
(750 μL); 6 mM Acetyl-coA (375 μL); 10 mM DTNB (75 μL). Store on ice.
Prepare daily.

35.

Reaction mixture for complex-I assay: Prepare a reaction mixture in a 1-mL
spectrophotometer disposable cuvette with final concentrations indicated (2.5
mM KP, pH 7.4; 3.5 g/L BSA; 60 μM DCPIP(2,6-dichlorophenol indophenol);
70 μM decylubiquinone; 1 μM AntimycinA) in 960 μL. Store on ice. Prepare
daily.

36.

Reagent Mixture-I for complex-II assay
Combine the following reagents in a 15 ml conical bottom tube
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■

0.3 M KCl; 25 mM Malate; 25 mM KCL; 7.5 mM KP Buffer (pH 7.4);
25 mM HEPES;

■

1.25 mM Phenazinemethosulfate; 2.5 μg/ml oligomycin; 0.5 mM ADP;
0.125 mM DCPIP

■

50 mM Succinate

■

Prepare Reagent Mixture-I fresh daily in each assay.

■

10 mL of the reagent mixture-I may be sufficient for one 96-well
microtiter plate; however, the user may reduce the volume based on the
experimental design.

Store on ice. Prepare daily.

Author Manuscript

37.

Reagent Mixture-II for complex-II assay
Combine 5 μg/ml AntimycinA; 5 μg/ml Rotenone; 5 mM KCN; 125 μM DCPIP
in 15 ml conical bottom tube. Store on ice. Prepare daily.

38.

Reduced Cyt c
•

Place 200 μL of 2 mM Cyt c(oxidized) in a 1.5 mL dark color microfuge
tube. Calculate the molarity based on the data provided by the vendor.

•

Add few crystals of sodium borohydride (NaBH4) to reduce Cyt

c(oxidized)

Author Manuscript

•

Incubate the mixture at 51oC for 1 hour

•

Add 4 drops of 0.1 N HCl to remove the excess NaBH4

•

Add 4 drops of 0.1 N NaOH to neutralize the mixture; mix well

•

Measure the final volume by an adjustable pipet and recalculate the
final concentration

•

Add 10 μL of the mixture in a 1 mL of quartz cuvette and scan for the
absorbance between 350 nm – 600 nm wavelength

•

A typical scan is shown in Figure 1

•

Divide Cyt c (reduced) preparation into 10–20 μL aliquots into 0.5 mL
dark color microfuge tubes and store aliquots at −20oC for 1 year.

Author Manuscript

39.

Resuspension Buffer: 0.32 M sucrose, 10 μM EGTA. Adjust pH to 7.5 with 1M
Tris base. Just before use, add benzamide, benzamidine-HCl, and AEBSF to the
buffer to reach a final concentration of 10 μM. Also, add the protease inhibitor
cocktail Set III per instructions of the manufacturer. Store on ice. Prepare daily.

40.

Rotenone stock solution (20 mM): Dissolve 26.8 mg Rotenone in 3.4 mL of
acetone. Protect from light and store at 4°C for 4–6 months.
This reagent is extremely toxic (utilized as an insecticide). Solubility: 20 mg/ml.
Although it is soluble in alcohol, acetone, and chloroform, we have found that
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acetone is the preferred solvent. Solution becomes slightly hazy at room
temperature.
41.

Reduced cytochrome c solution (Spinazzi et al., 2012)

Author Manuscript
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■

Dissolve 110 mg of ascorbic acid in 1 mL of 10 mM potassium
phosphate buffer (pH 7.0), and then add a few grains of Tris powder to
obtain a pH of 6.5–6.8.

■

Dissolve 250 mg of cytochrome c in 1.2 mL of 10 mM potassium
phosphate buffer (pH 7.0), and then add 0.3 mL of ascorbic acid
solution

■

Incubate with agitation for 1 h at 4⁰C. The reduction of cytochrome c
will result in a color shift from brown to pink-orange.

■

Purify from excessive ascorbic acid in solution using a PD10
disposable desalting column previously equilibrated with 50 ml 1o 10
mM potassium phosphate buffer (pH 7.0). Discard the first three drops,
and then collect the eluted solution of reduced cytochrome c in several
1.5 mL micro tubes. Store the vials on ice.

■

To check the efficiency of cytochrome c reduction and to assess the
absence of residual ascorbic acid in the solution, read for 2 min the
absorbance of a 50 μM cytochrome c solution in a 1-mL cuvette at 550
nm. The decrease in absorbance should not exceed 0.005 per min.

■

Dissolve a few crystals of potassium ferricyanide in 10 ml of water
under a chemical hood. Add to the cuvette 1 μL of a diluted potassium
ferricyanide solution. This will result in cytochrome c oxidation.
Measure the absorbance at 550 nm for 3 min.

■

Add a few crystals of sodium dithionite and read the absorbance again.
The initial absorbance values before the addition of dithionite should
be about 95% of the values after dithionate addition.

■

Discard any vials showing signs of auto reduction and pool together the
selected vials.

■

Aliquots of this solution can be stored under the liquid nitrogen for
several years

Author Manuscript

37

Sodium phosphate (dibasic)(100 mM)/ EDTA (5mM)buffer (pH 7.5):
Dissolve 1.42 g sodium phosphate (dibasic) in approximately 50 mL of
nanopure water. Add 1ml of 0.5 M EDTA. Adjust pH to 7.5 with 1N NaOH.
Adjust the final volume to 100 mL Store at 4°C for 1–2 years. Check pH before
use.

38

Succinate (0.5 M): Dissolve 0.81 g succinic acid (disodium salt) in 5 mL of
water. Adjust pH to 7.4 with 3 M KOH. Adjust the volume to 10 mL with water.
Store in 0.25 mL aliquots at 4oC for 4–6 months.
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User can adjust the stock volume based on needs. Solubility of Succinic acid:
100 mg/ dL water at room temperature.
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39

Sucrose (1 M): Dissolve 34.2 g sucrose in 100 mL of water. Aliquot in small
volumes and store at −20°C for 1 year.

40

Sucrose Density Gradient Buffer: Prepare buffer containing 120 mM KCl, 20
mM Tris/HCl, 5 mM dihydrogen potassium phosphate, 2 mM EGTA, pH 7.4,
and add sucrose to prepare solutions of 10%, 28.5%, and 34% w/v to be used in
the discontinuous sucrose density gradients. Store at room temperature and
prepare daily.

41

Synaptosome Lysis Buffer: 3 mM Tris-HCl, pH 8.5. Add benzamide,
benzamidine-HCl, AEBSF, and protease inhibitor cocktail at the same
concentrations as in the Resuspension Buffer. Store on ice and prepare daily.

42

Tris-HCL Buffer, pH 8.0 (1M): Dissolve 121 g Tris base in 800 mL distilled
water. Adjust pH 8.0 by adding 58.4 mL 0.1M HCL at 25°C. Adjust final
volume to 1L with distilled water. Filter the solution through a 0.45-μm filter
and store at 4°C up to 1 year. Check pH before use.

40.

TTFA [2-Thenoyltrifluoroacetone] (50 mM): Dissolve 11.1 mg 2Thenoyltrifluoroacetone in 1 mL of 95% ethanol. Although storing at 4°C for
several weeks is reported, daily preparation is recommended. Alternatively,

TTFA can be dissolved in DMSO.
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41.

Tween 20 solution (2.5% vol/vol). Dissolve 200 μL of Tween-20 in 7.8 mL of
distilled water. Store at room temperature until use. Daily preparation is
recommended.

42.

42.Ubiquinone solution (10 mM). Dissolve 2.0 mg of ubiquinone in 0.8 mL of
absolute ethanol and store it in 100 μL aliquots at −20⁰C for 4–6 months.

COMMENTARY
Background Information

Author Manuscript

Many human diseases are closely relevant to mitochondrial dysfunction. Technological
advancement, new assay platforms, and newly discovered features of mitochondria
homeostasis have placed the “cell bioenergetics” in a pivotal stage. These observations were
followed by ones that linked mitochondria to cell respiration, characterized their structure by
electron microscopy, purified them using techniques of cell fractionation, characterized the
bioenergetic processes associated with these organelles, identified intra-mitochondrial DNA,
RNA, and protein synthesis, and linked mitochondrial abnormalities to disease states or
toxicological events (Trushina & McMurray, 2007)
The mitochondrial medicine as a new emerging discipline still owes its existence to pioneer
studies in the late 1940s and 1950s. In spite of significant progress and advances in
bioenergetics, major issues remain mainly related with experimental design and user
friendly, cost effective homemade reagent-based protocols.
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In this protocol, we aimed (1) to provide simple, straightforward, reproducible
mitochondria- enriched sample preparation from the rodent brain tissue for enzymatic assays
and (2) to offer two modes of reaction platform (i.e., 96-well microtiter plate (highthroughput) and single cuvette assay. Depending on the preference and availability of the
laboratory equipment, the users will have the options to design and perform their assays.
Critical Parameters
Protease inhibitor cocktails must be included in mitochondria-enriched sample preparation.
Protein aliquots should be more concentrated so that minimum volume (1–3 μL) would
provide required protein concentration per well or 1–2 μg per cuvette.
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Avoid repeated freezing-thawing cycle. Aliquot the samples into small volume. Label the
leftover sample if user wants to use for some other purposes. The kinetic assays are
temperature sensitive. Make sure that microplate reader and spectrophotometer are
temperature controlled. pH is also dependent on the temperature. Measure the pH of the
reaction buffers at the same temperature of reaction (e.g. if the kinetic assay measurement
uses 30°C, then buffer pH should be adjusted at 30°C when prepared). In 96-well micro
titrate plate modality; the sample assay replication should be measured at a minimum in
“triplicates (3x)”. In some cases, “quintuplicate” (5x) readings should be considered. Use the
same brand-named 96-well microtiter plate in the kinetic assay measurements. That will
minimize plate-to-plate variation. The reagent addition order in protocols is important. Spot
the starter reagent on the side shown in Figure 10. Set your microplate reader’s internal
shaker for 5 second at “medium level”. This shaking will allow reagent droplets to be mixed
in all 96-wells and the reaction starts at the same time.
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Troubleshooting
Use low-binding quality pipet tips since small protein sample pipetting is critical Wash the
pipet tips 3–4 times in the buffer solution in the well to make sure that all protein solution is
delivered. Always run spectrum analysis and physically observe the “peak” for Cytochrome
c (reduced) (Fig. 1), DCPIP (Fig. 1). Never assume that your preparation yields the expected
product.
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If inhibitors of mitochondria do not work in your first experiment, take the following
actions: (a) Check your oligomycinA expiration date. OligomycinA is stable in either 100%
ethanol or DMSO for only 6 months when kept at −20°C (b) If the concentration suggested
in these protocols did not work, then run concentration titration. Minimum fiveconcentration points (i.e. two upper level concentration, two- lower level concentration, and
one suggested concentration in this protocol). Never use the leftover reagents from the
previous experiment; therefore, we suggest small volume aliquots. Discarding the 96-well
microtiter plate and single disposable cuvettes is critical. Dispose them in biohazardous bin
as they contain toxic mitochondria inhibitors.
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Although we did not present any data obtained from these protocols, users should be
mindful to monitor coefficient of variation (CV%) of their inter-run assays. Reproducibility
is important and users should establish their CV%. The formula we used is shown here as
CV = Standard Deviation (SD) / Mean (Ⱦ) * 100
We recommend the users to operate CV= 10–20% in this kind of assays.
Anticipated Results
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These protocols provide easy to follow steps with sensitive and reproducible measurement of
catalytic activities of mitochondria electron transfer cascade (ETC) enzymes. The user
should calculate the enzymatic activities for each mitochondrial ETC according the equation
provided under the corresponding protocols.
In mitochondria swelling assay, ΔA540nm = 0.5 indicates that mitochondrial membrane is
leaky therefore mitochondria swelling is completed.
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Users should calculate the pathlength (𝓁, cm) based on the brand of 96-well micro titrate
plate. (see SUPPORT PROTOCOL 3). About 10 μg mitochondria-enriched protein solution
provides a good enzymatic kinetic profile in 96-well micro titrate plate format. In case of
somatic and synaptic mitochondria-enriched preparation, 30–40 μg protein can provide
measurable enzyme kinetics. Specific activity of each enzyme complex is expressed as μmol
min-1 mg-1 protein. The specificity of Complex-I and Complex I-III activities can be
calculated by enzyme complex activity [Total, (−) rotenone] – enzyme complex activity [(+)
rotenone]. Specificity of these complexes is expected to be around 85%. Complex-II reaction
mixture (Reaction mixture-II) includes set of inhibitors (rotenone, AntimycinA and KCN)
that differentiate total Complex-II specific activity. To include 10 mM (final) malonate of 50
mM (final) 2-theonyltrifluoroacetone (TTFA) will inhibit Complex-II. The specific activity
of Complex-II with and without malonate (or TTFA) will determine the specificity of
Complex-II. Complex II-III specificity is determined by including 10uM (final) malonate
and 1mg/ml (final) AntimycinA in the reaction in a separate set of well in the same assay
setting. Complex-III specific activity is calculated by subtracting total activity [(−)
AntimycinA] from AntimycinA resistant activity [ (+) AntimycinA]. Specificity of the
Complex-III is expected at around 80%. Complex-IV specificity is determined by inclusion
or exclusion of KCN.
Time Considerations
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The purification of somatic and synaptic mitochondria and mitochondria-enriched protein
suspension from different regions of rodent brain is a lengthy process (a day-long process).
Using this procedure, you may process the brains obtained from 6 to 8 rodents (rats or mice)
in a given day. Each preparation requires careful handling as the preparation protocol
requires multiple steps. The number of animals used in preparation is also critical. We do
recommend users to process maximum 4 rodent brains in a preparation. Enzyme kinetic
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assays requires relatively short period including pipetting. 2 hours per assay is a reasonable
time to spend.
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Significance Statement
Mitochondrial bioenergetics are critical for normal central nervous system (CNS)
function. Abnormal bioenergetics due to malfunctioning of mitochondrial enzymes of the
electron transfer cascade (ETC) are associated with both CNS diseases and the effects of
CNS toxic agents. The cellular complexity of the CNS and the structural complexity of
the ETC enzymes present challenges for those wishing to assess functional changes in
CNS mitochondria.
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Protocols for the isolation of mitochondria from distinct brain regions and subcellular
compartments of neurons, as well as for the conduct of ETC enzyme assays in multiplex
format at microliter levels employing new analyzers, software for data analysis, and
advanced chemical formulations of substrates, should be of assistance to investigators
planning to study CNS mitochondrial function.
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Fig.1.

Isolation of mitochondria-enriched pellet by Ficoll density gradient centrifugation. First, add
8% Ficoll solution into centrifugation tube. Second, add 14% Ficoll solution. From bottom
of the tube without mixing with 8% Ficoll gradient. Finally, add P2 pellet. Resuspension on
the top of the centrifugation tube without mixing the gradient.
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Fig.2.

Dissection steps for slices of cerebellum. A: View of the dorsal surface of the rat brain.
Positions of transverse cuts (1 and 2; dashed lines) to isolate cerebellum and pons are
indicated. B: View of block of tissue from A. Positions of slanting cuts (1 and 2; dashed
lines) to separate the cerebellum from underlying pons are indicated (Robertson, Zimmer, &
Gahwiler, 1989).
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Fig.3.

Schematic surgical procedure for the fast removal of hippocampus from rat brain. A: Two
parasagittal incision at a 30° angle (1 and 2) . B: Separation of the central cortex area (1 and
2). C: Removal of two hippocampal formations (1). This illustration was adopted and
professionally re-drawn (Navarro et al., 2008)
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Fig.4.

Schematic representation of Prefrontal Cortex dissection. A: Removal of olfactory bulb. B:
Dissection of prefrontal cortex. This section mainly contains motor cortex.
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Fig.5

. Glass-Glass paste Dounce homogenizer with 2 ml volume. This homogenizer is suitable for
mitochondria-enriched pellet (P2) homogenization without damaging the integrity of the
mitochondria. A gentle hand-driven homogenization is recommended.
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Fig.6.

Schematic illustration of mitochondria-enriched sample preparation by differential
centrifugation method.
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Fig.7.

Mitochondria Swelling. Mitochondria scatter light in cells and tissue at visible wavelength
(λ=540 nm). Simple optical transmission measurements are sensitive to changes in
mitochondria intactness during the preparation. Majority of mitochondria during the
preparation did not swell in this test as the absorbance did not dramatically change (ΔA540nm
= 0.05).
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Fig.8.

A representative scan for demonstrating the formation of reduced Cytochrome c
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Fig.9.

DCPIP scanning graph. The maximal peak at 600 nm indicates chemically stable DCPIP.
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Fig.10.

Pipetting the reagent on the side of the micro titer well. The reaction starter reagent either
stays on the wall or slightly mixes with the well content.
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Table 1:
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Complex-I assay flow chart
REAGENTS

BLANK

SAMPLE
(−) Rotenone

SAMPLE
(+) Rotenone

(1) 50 mM KP Buffer

241 μL

241 μL – x μL

238.5 μL – x μL

(2) Protein solution

-

X μL

X μL

(3) 0.2 M KCN

2.5 μL

2.5 μL

2.5 μL

(4) 5 mM NADH

2.5 μL

2.5 μL

2.5 μL

(5) 1 mM Rotenone

2.5 μL

-

2.5 μL

(6) Read the baseline A340nm for 2 minutes
(7) Start the reaction by adding 1.6 mM decylubiquinone

1.5 μL

1.5 μL

1.5 μL

(8) Read the absorbance at A340nm for 2–3 minutes
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Table 2:

Author Manuscript

Complex I-III assay flow-chart
REAGENTS

BLANK

(1) 50 mM KP Buffer

235 μL

(2)Protein solution

-

(3)0.2 mM KCN
(4)4 mM Cyt-c (oxidized)
(5)1.0 mM Rotenone

SAMPLE
(−) Rotenone)

232.5 – x μL

235 –x μL

X μL

X μL

2.5 μL

2.5 μL

2.5 μL

5 μL

5 μL

2.5 μL

(6) START the reaction by adding 5 mM NADH

SAMPLE
(+) Rotenone

5 μL

5 μL

5 μL
2.5 μL
5 μL

(7) Measure the absorbance at A550nm for 10 min
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Table 3:
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Complex II assay flow-chart
REAGENTS

BLANK

SAMPLE
(−)
Malonate

SAMPLE
(+)
Malonate

(1) Water

85 μL

95 – x μL

85-x μL

(2) Protein solution

-

X μL

X μL

(3) Reagent Mixture-I

100 μL

100 μL

100 μL

(5) Reagent Mixture-II with a brief mixing

50 μL

50 μL

50 μL

(6) Add 1M Malonate

10 μL

-

10 μL

5 μL

5 μL

(4) Incubate the plate at 300C for 10 min with a gentle agitation

(7) Start reaction by adding 2.5 mM DB(8) Measure the absorbance at A600nm for 3–5 min

5 μL
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Table 4:

Author Manuscript

Complex II-III assay flow-chart
REAGENTS

BLANK

(1) 0.1 M KP buffer, pH 7.4
(2) Protein solution

217 μL
-

SAMPLE
(−) Malonate

SAMPLE
(+) Malonate

227-x μL

217-x μL

X μL

X μL

(3) 50 μM KCN

10 μL

10 μL

10 μL

(4) 0.5M Succinate

10 μL

10 μL

10 μL

(5) Mix and pre-incubate the plate at 30°C for 20 min
(6) 1M Malonate

10 μL

-

10 μL

(7) Start reaction by adding 2.5 mM cytochrome-c (oxidized)

3μL

3μL

3μL

(8) Measure the absorbance at A550nm for 3–5 minutes
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Table 5:

Author Manuscript

Complex III assay flow-chart
REAGENTS

BLANK

SAMPLE
(−) AntimycinA

SAMPLE
(+) AntimycinA

(1) Reaction Buffer for Complex-III

225 μL

227.5 – x μL

225 – x μL

(2) 50 mM KCN

10 μL

10 μL

10 μL

(3) 1.25 mM Cyt c (oxd.)

10 μL

10 μL

10 μL

(4) 1 mM AntimycinA

2.5 μL

-

2.5 μL

-

X μL

X μL

2.5 μL

2.5 μL

2.5 μL

(5) Protein solution
(6) Incubate the plate with a gentle mixing for 10 at 30°C
(7) Start the reaction by adding 5 mM DBH2
(8) Measure the absorbance at A550nm for 2–3 minutes
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Table-6:

Author Manuscript

Complex IV assay flow-chart
BLANK

SAMPLE
(−) KCN

SAMPLE
(+) KCN

230 μL

240 μL–

230 μL –xμL

REAGENTS

(1)O.1 M KP Buffer (pH 7.4)
(2)Protein solution

-

X μL

X μL

(3)50 mM KCN

10 μL

-

10 μL

(3) Start the reaction by adding 0.5 mM Cyt-c (reduced)

10 μL

10 μL

10 μL

(4) Measure the absorbance at A550nmfor 10 min
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Table 7
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Citrate synthase assay flow-chart
REAGENTS

BLANK

SAMPLE

(1) Water

197.5 μL

197.5 μL – x μL

(2) Reaction mixture for citrate synthase reaction

40 μL

40 μL

(3) Protein solution Incubate the plate for 5 min at 30°C

-

X μL

(4) Start the reaction by adding 10 mM oxaloacetic acid

12.5 μL

12.5 μL

(5) Measure the absorbance at A412nm for 3–4 min.
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